Global Metabolomics Market (2020 to 2025) - Biomarker Development Presents Opportunities

DUBLIN, Jan. 8, 2021 /PRNewswire/ -- The "Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery,Functional Genomics), Indication (Cardiology, Oncology,Inborn Errors), End User (Academic Institute, CROs) - Global Forecast to 2025" report has been added to's offering.

The global metabolomics market size is projected to reach USD 4.1 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 13.4% during the forecast period.

The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine, and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry. However, issues related to data examination & data processing in metabolomics and the high cost of tools and instruments are likely to restrain the market growth to a certain extent.

By Product & Service, the metabolomics instrument accounted for the largest share of the metabolomics market.

The metabolomics instrument segment is expected to account for the largest market share in 2020. Factors such as the technological advancements in analytical instruments in terms of miniaturization, automation, and computerization; increase in the number of research-related activities worldwide in the field of medicine, nutraceuticals, and metabolomics; and strengthening healthcare infrastructure in developing nations for efficient disease diagnosis and treatment are expected to propel the growth of this segment during the forecast period

By application, the biomarker discovery segment accounted for the largest share of the metabolomics market.

The biomarker discovery segment is expected to account for the largest market share in 2020. The use of metabolic biomarkers to assess the pathophysiological health status of patients is increasing. In recent years, as a result of significant technological advancements, metabolomics has become a vital tool in discovering biomarkers.

By Indication, the Cancer segment expected to grow at the fastest growth rate during the forecast period.

Based on indication, the metabolomics market has been segmented into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications (respiratory and infectious diseases. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent
increase in the demand for cancer therapies.

By End-user, Academic and Research Institutes accounted for the largest share of the metabolomics market.

The academic and research institutes segment accounted for the largest share of the metabolomics market in 2020. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.

Asia Pacific: The fastest-growing region in the metabolomics market.

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

North America: The largest share of the metabolomics market.

North America, which includes the US and Canada, accounted for the largest share of the metabolomics market. The large share of the North America region can be attributed to the presence of major players operating in the metabolomics market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Metabolomics Market Overview
4.2 Asia-Pacific: Metabolomics Market Share, by Product and Service and by Country (2019)
4.3 Metabolomics Market Size, by Detection Tools
4.4 Metabolomics Market Share, by Separation Tools, 2020 Vs. 2025

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Key Market Drivers Availability of Government and Private Funding for Metabolomics Research Increasing Pharmaceutical and Biotech R&D Expenditure Growing Demand for Personalized Medicine
5.2.2 Key Market Restraints Issues Related to Data Examination and Processing High Cost of Tools and Instruments
5.2.3 Key Market Opportunities Biomarker Development Lucrative Opportunities in Emerging Markets
5.2.4 Key Market Challenges Complexity and Diversity of Biological Samples Dearth of Skilled Researchers
5.3 Impact of COVID-19 on Growth of Metabolomics Market

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Increasing Adoption of Hyphenated Technologies
6.2.2 Tie-Ups Between Instrument Manufacturers and Research Laboratories/Academic Institutions
6.3 Regulatory Analysis

7 Technology Investment Potential
7.1 Introduction
7.2 Investment Client Networks
7.3 Funding Bodies/Initiatives
7.4 Analysis of Potential Areas for Technology Investment Using Strategic Evaluation
7.4.1 Parameters Considered for Emerging Opportunity Evaluation Level of Attractiveness Probability of Success
7.4.2 Opportunity Strategic Evaluation Analysis
7.4.3 Description of Opportunities Viable (Quadrant 1) - Biomarker Discovery and Lead Optimization in Drug Discovery Biomarker Discovery Lead Optimization in Drug Discovery Toxicity Testing Promising (Quadrant 2) - Companion Diagnostics for Personalized Medicine and Nutrigenomics Companion Diagnostics for Personalized Medicine Nutrigenomics Agriculture Challenges (Quadrant 3) - Environmental Metabolomics Environmental Metabolomics Functional Genomics

8 Metabolomics Market Size, by Product and Service
8.1 Introduction
8.2 Metabolomics Instruments
8.2.1 Separation Tools
8.2.2 High-Performance Liquid Chromatography Growing Use of Hplc in High-Growth Applications to Drive Market Growth
8.2.3 Gas Chromatography Technological Advancements in Gas Chromatography to Drive Adoption of Gc in Metabolome Study
8.2.4 Ultra-Performance Liquid Chromatography Higher Chromatographic Efficiency and Sensitivity of Uplc Would Drive Market Growth
8.2.5 Capillary Electrophoresis Ce is Used in Pathology/Clinical Laboratories Worldwide due to the Low Cost of Reagents, Enhanced Accuracy, and Ease of Operation
8.2.6 Detection Tools
8.2.7 Mass Spectrometry Increasing Use of Mass Spectrometry in Cancer and Genetic Disease Research is Propelling Its Demand
8.2.8 Nuclear Magnetic Resonance Spectroscopy
8.2.9 Surface-Based Mass Analysis Applicability of Surface-Based Mass Analysis Technology in a Wide Range of Samples Would Drive Its Growth
8.3 Metabolomics Bioinformatics Tools & Services
8.3.1 Bioinformatics Services Bioinformatics Services Offer a Simplified Way to Derive Insights from Metabolomics Research
8.3.2 Bioinformatics Tools & Databases Application of Bioinformatics Tools & Databases in Translational Research to Fuel Market Growth

9 Metabolomics Market Size, by Application
9.1 Introduction
9.2 Biomarker Discovery
9.3 Drug Discovery
9.4 Toxicology Testing
9.5 Nutrigenomics
9.6 Personalized Medicine
9.7 Functional Genomics
9.8 Other Applications

10 Metabolomics Market Size, by Indication
10.1 Introduction
10.2 Cancer
10.3 Cardiovascular Disorders
10.4 Neurological Disorders
10.5 Metabolic Disorders
10.6 Inborn Errors of Metabolism
10.7 Others

11 Metabolomics Market Size, by End-user
11.1 Introduction
11.2 Academic Research Institutes
11.3 Pharmaceutical and Biotechnology Companies
11.4 Contract Research Organizations (Cros)
11.5 Others

12 Global Metabolomics Market Size, by Region
12.1 Introduction
12.2 North America
12.3 Europe
12.4 Asia-Pacific
12.5 Latin America
12.6 Middle East & Africa

13 Competitive Landscape
13.1 Overview
13.2 Market Share Analysis (2019)
13.3 Key Market Developments
13.3.1 Product Launches
13.3.2 Acquisitions
13.3.3 Partnerships, Collaborations, and Agreements
13.3.4 Expansions

14 Company Evaluation Matrix
14.1 Overview
14.2 Competitive Leadership Mapping: Major Market Players (2019)
14.2.1 Stars
14.2.2 Emerging Leaders
14.2.3 Pervasive
14.2.4 Participants
14.3 Company Profiles
14.3.1 Thermo Fisher Scientific Inc.
14.3.2 Agilent Technologies, Inc.
14.3.3 Waters Corporation
14.3.4 Danaher Corporation
14.3.5 Shimadzu Corporation
14.3.6 Bio-Rad Laboratories, Inc.
14.3.7 Bruker Corporation
14.3.8 Perkinelmer, Inc.
14.3.9 Merck KGaA
14.3.10 GE Healthcare
14.3.11 Hitachi High-Technologies Corporation
14.3.12 Human Metabolome Technologies, Inc.
14.3.13 Leco Corporation
14.3.14 Metabolon, Inc.
14.3.15 Dani Instruments
14.3.16 Scion Instruments
14.3.17 Gl Sciences
14.3.18 Sri Instruments
14.3.20 Kore Technology
14.3.21 Jasco, Inc.

15 Appendix

15.1 Discussion Guide
15.2 Knowledge Store
15.3 Available Customizations

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets